CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

NCT00033267 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Recurrent Mantle Cell Lymphoma

Interventions

DRUG: temsirolimus

Sponsor

National Cancer Institute (NCI)